Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

Moschini M, Soria F, Susani M, Korn S, Briganti A, Rouprêt M, et al. Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. Bladder Cancer. 2017;3(3):161-169.

Liang K, Liu F, Fan J, Sun D, Liu C, Lyon CJ, et al. Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and Treatment Monitoring. Nat Biomed Eng. 2017;1.

Giulino-Roth L, van Besien HJ, Dalton T, Totonchy JE, Rodina A, Taldone T, et al. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma. Mol Cancer Ther. 2017;16(9):1779-1790.

Gratzinger D, de Jong D, Jaffe ES, Chadburn A, Chan JK, Goodlad JR, et al. T- and NK-Cell Lymphomas and Systemic Lymphoproliferative Disorders and the Immunodeficiency Setting: 2015 SH/EAHP Workshop Report-Part 4. Am J Clin Pathol. 2017;147(2):188-203.

Gullett JC, Westblade LF, Green DA, Whittier S, Burd EM. The Brief Case: Too Beta To Be a "B". J Clin Microbiol. 2017;55(6):1604-1607.

Nguyen GH, Olson LC, Magro CM. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome. Ann Diagn Pathol. 2017;28:54-59.

Ebot EM, Gerke T, Labbé DP, Sinnott JA, Zadra G, Rider JR, et al. Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. Cancer. 2017;123(21):4130-4138.

Magro CM, Olson LC, Nguyen GH, de Feraudy SM. CD30 Positive Lymphomatoid Angiocentric Drug Reactions: Characterization of a Series of 20 Cases. Am J Dermatopathol. 2017;39(7):508-517.

S Wu P, Cooper BT, Bu F, Bowman CJ, J Killian K, Serrano J, et al. DNA Methylation-Based Classifier for Accurate Molecular Diagnosis of Bone Sarcomas. JCO Precis Oncol. 2017;2017.

Magro CM, Davis TL, Kurtzman DJ. Epidermotropic marginal zone lymphoma: An uncommon cutaneous B-cell lymphoma responsive to rituximab. JAAD Case Rep. 2017;3(6):474-476.